Cartesian Therapeutics Long Term Debt

Cartesian Therapeutics (RNAC) currently reports a long-term debt of $14M as of June 2026. That compares with $19M in the prior-year period — down 28.8% year over year. Use the charts on this page to explore Cartesian Therapeutics's long-term debt history and peer comparisons.

Cartesian Therapeutics's long-term debt decreased from $19M to $14M — a 28.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cartesian Therapeutics reported $14M in long-term debt as of June 2026. That compares with $19M in the prior-year period — down 28.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cartesian Therapeutics, and consider following RNAC for alerts when major investors trade the stock.

Cartesian Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNAC with unrelated industries.